GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » bioAffinity Technologies Inc (NAS:BIAF) » Definitions » 5-Year RORE %

bioAffinity Technologies (bioAffinity Technologies) 5-Year RORE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is bioAffinity Technologies 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. bioAffinity Technologies does not have enough data to calculate 5-Year RORE %.


bioAffinity Technologies 5-Year RORE % Historical Data

The historical data trend for bioAffinity Technologies's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioAffinity Technologies 5-Year RORE % Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
5-Year RORE %
- - - -

bioAffinity Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of bioAffinity Technologies's 5-Year RORE %

For the Diagnostics & Research subindustry, bioAffinity Technologies's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


bioAffinity Technologies's 5-Year RORE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where bioAffinity Technologies's 5-Year RORE % falls into.



bioAffinity Technologies 5-Year RORE % Calculation

bioAffinity Technologies's 5-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 5-year before.


bioAffinity Technologies  (NAS:BIAF) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


bioAffinity Technologies 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of bioAffinity Technologies's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


bioAffinity Technologies (bioAffinity Technologies) Business Description

Traded in Other Exchanges
N/A
Address
22211 W Interstate 10, Suite 1206, San Antonio, TX, USA, 78257
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
Executives
Roby Joyce director 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Xavier Trinidad Reveles officer: Chief Operating Officer 22211 W INTERSTATE 10, SUITE 1206, SAN ANTONIO TX 78257
Michael Philip Dougherty officer: Chief Financial Officer 2934 SCATTERED OAKS ST, SAN ANTONIO TX 78232
James Michael Edwards officer: Chief Financial Officer 30907 KEENELAND DRIVE, FAIR OAKS RANCH TX 78015
Peter S Knight director 6702 STEIN CIRCLE, #642, P.O. BOX 4138, PARK CITY UT 84060
Steven Girgenti director, officer: Executive Chairman C/O HEALTHWORLD CORP, 100 AVENUE OF THE AMERICAS, NEW YORK NY 10013
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Gary D Rubin director, 10 percent owner 2080 NW BOCA RATON BLVD, STE 2, BOCA RATON FL 33431
Stuart Diamond director 498 SEVENTH AVE, NEW YORK NY 10018
Maria Zannes director, officer: President, CEO 19702 BELLA LOMA, #6005, SAN ANTONIO TX 78256
Harvey Sandler Revocable Trust 10 percent owner 21170 N. E. 22ND COURT, NORTH MIAMI BEACH FL 33180
Mohsin Y Meghji director C/O LOUGHLIN MEGHJI + COMPANY, NEW YORK NY 10016
Vivienne I Rebel officer: EVP, Chief Sci. & Med. Officer 8922 APACHE TRAIL, SAN ANTONIO TX 78255
Timothy P Zannes officer: Secretary, EVP, Gen. Counsel 1510 VISTA LARGA CT. NE, ALBUQUERQUE NM 87106
Nathan M Perlmutter 10 percent owner 28 PARRISH POND LANE, SOUTHAMPTON NY 11968